Understanding What Rare Disease Did Pfizer Lay Off and Its Broader Implications
•
4 min read
Following a Phase 3 clinical trial failure in June 2024, Pfizer officially quit its experimental gene therapy program for Duchenne muscular dystrophy (DMD) and subsequently laid off staff involved in the project. This was just one part of a wider strategic reassessment that led to job cuts and the discontinuation of other rare disease efforts, providing a sobering glimpse into the high-stakes world of biopharmaceutical research.
